Skip to Content
Merck

Y0000516

Glimepiride for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Glimepiride

Slide 1 of 1
Sign In to View Organizational & Contract Pricing.

Select a Size

12 μG

1 530,00 kr

1 530,00 kr

Please contact Customer Service for Availability
Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C24H34N4O5S
CAS Number:
93479-97-1
Molecular Weight:
490.62
NACRES:
NA.24
PubChem Substance ID:
329830997
UNSPSC Code:
41116107
MDL number:
MFCD00878417

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Glimepiride for system suitability, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

SMILES string

CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O

InChI key

WIGIZIANZCJQQY-RUCARUNLSA-N

grade

pharmaceutical primary standard

API family

glimepiride

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
Y00005151292303BP1144
Glimepiride for system suitability European Pharmacopoeia (EP) Reference Standard

Y0000516

Glimepiride for system suitability

Glimepiride European Pharmacopoeia (EP) Reference Standard

Y0000515

Glimepiride

Glimepiride United States Pharmacopeia (USP) Reference Standard

USP

1292303

Glimepiride

Glimepiride British Pharmacopoeia (BP) Reference Standard

BP1144

Glimepiride

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

manufacturer/tradename

USP

manufacturer/tradename

BP

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical
pharmaceutical small molecule

format

neat

format

neat

format

neat

format

neat

API family

glimepiride

API family

glimepiride

API family

glimepiride

API family

glimepiride

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

-

storage temp.

2-8°C

Application

Glimepiride is currently used to treat type 2 diabetes.

Biochem/physiol Actions

Glimepiride is a potent blocker of cardiac KATP channels activated by pinacidil with an IC50 of 6.8 nM.
Potent blocker of cardiac KATP channels.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

comparable product

Product No.
Description
Pricing

related product

Product No.
Description
Pricing

1292325

Glimepiride Related Compound B, United States Pharmacopeia (USP) Reference Standard

1292314

Glimepiride Related Compound A, United States Pharmacopeia (USP) Reference Standard

1292336

Glimepiride Related Compound C, United States Pharmacopeia (USP) Reference Standard

1292347

Glimepiride Related Compound D, United States Pharmacopeia (USP) Reference Standard

Y0001742

Glimepiride for impurity A identification, European Pharmacopoeia (EP) Reference Standard

PHR1727

Glimepiride Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1725

Glimepiride cis-Isomer (Glimepiride Related Compound A), Pharmaceutical Secondary Standard; Certified Reference Material

PHR1726

Glimepiride Sulfonamide, pharmaceutical secondary standard, certified reference material

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361

Hazard Classifications

Repr. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Elham A Mohamed et al.
AAPS PharmSciTech, 13(3), 1013-1023 (2012-07-31)
Effects of tromethamine (Tris), polyvinylpyrrolidone (PVP-K25), and low molecular weight chitosan (LM-CH) on dissolution and therapeutic efficacy of glimepiride (Gmp) were investigated using physical mixtures (PMs), coground mixtures, coprecipitates (Coppts) or kneaded mixtures (KMs), and compared with drug alone. Fourier
DPP-4 inhibition and neuroprotection: do mechanisms matter?
Richard P Shannon
Diabetes, 62(4), 1029-1031 (2013-03-23)
Mitsuyoshi Takahara et al.
Endocrine journal, 59(12), 1131-1136 (2012-08-02)
We retrospectively investigated the effect of adding dipeptidyl peptidase-4 (DPP-4) inhibitor and tapering sulfonylurea on blood glucose fluctuation in Asian patients with type 2 diabetes mellitus under basal-supported oral therapy (BOT). We recruited twenty-two consecutive Japanese patients with type 2
Shinzo Hiroi et al.
Diabetes technology & therapeutics, 15(2), 158-165 (2013-01-08)
This study aimed to determine the efficacy and safety of pioglitazone/glimepiride as a fixed-dose combination (FDC) in Japanese patients with type 2 diabetes. In this multicenter, phase III, open-label evaluation, eligible patients had to have a glycosylated hemoglobin (HbA(1c)) level
J L Mateos et al.
Drugs of today (Barcelona, Spain : 1998), 48 Suppl B, 1-17 (2012-10-20)
New drugs for type 2 diabetes that act on incretin metabolism have been shown to improve glycemic control, reduce body weight and have a low risk for hypoglycemia. Among these, liraglutide is the first glucagon-like peptide 1 (GLP-1) analogue approved
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service